GlassScriptPhysician profile
Meagan E Gilbert
NPI 1457753410
$10,762.68
in general payments reported to CMS, 2019-2025
33 companies · $2,893 in 2025
The $2,893 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,726 · 2022: $1,842 · 2023: $1,104 · 2024: $2,198 · 2025: $2,893.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,110 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,110.49 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,149.51 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,413.43 | 2021-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,036.38 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $1,013.69 | 2021-2025 | Tremfya, Stelara, Simponi |
| Regeneron Healthcare Solutions, INC. | $439.85 | 2022-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $314.36 | 2021-2024 | Ocaliva |
| Aimmune Therapeutics, INC. | $298.11 | 2024-2025 | Zenpep, Vowst |
| Genzyme Corporation | $294.31 | 2022-2025 | |
| Madrigal Pharmaceuticals | $232.56 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $227.33 | 2024-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $210.78 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $203.97 | 2021-2022 | |
| Daiichi Sankyo INC. | $190.43 | 2021-2022 | |
| Qol Medical, LLC | $176.08 | 2021-2025 | Sucraid, Sucraid |
| Celgene Corporation | $170.19 | 2021-2024 | Zeposia |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $137.77 | 2023-2025 | Ibsrela |
| Evoke Pharma, INC. | $137.51 | 2023-2025 | Gimoti |
| Nestle Healthcare Nutrition INC. | $137.11 | 2021-2023 | |
| Pfizer INC. | $128.37 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $108.31 | 2021 | |
| Vivus LLC | $102.46 | 2021-2025 | Qsymia, Pancreaze |
| Celltrion USA INC. | $100.98 | 2025 | Vegzelma |
| Ipsen Biopharmaceuticals, INC | $93.39 | 2024-2025 | Iqirvo, Bylvay |
| Pharmacosmos Therapeutics INC. | $76.71 | 2021 | |
| Redhill Biopharma INC. | $65.27 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $64.61 | 2022-2024 | Dificid, Zerbaxa |
| Amgen INC. | $62.96 | 2021-2023 | Avsola, Amjevita |
| Gilead Sciences, INC. | $62.32 | 2021 | |
| Organon LLC | $46.26 | 2022-2024 | |
| Braintree Laboratories, INC. | $19.23 | 2025 | Suflave |
| Ethicon US, LLC | $17.78 | 2021 | |
| Novo Nordisk INC | $16.45 | 2025 | Wegovy |
| Fresenius Kabi USA, LLC | $14.21 | 2023 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meagan Gilbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.